Skip to main content
Top
Published in: Supportive Care in Cancer 12/2005

01-12-2005 | Original Article

Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies

Authors: Corrado Girmenia, Giuseppe Cimino, Francesca Di Cristofano, Alessandra Micozzi, Giuseppe Gentile, Pietro Martino

Published in: Supportive Care in Cancer | Issue 12/2005

Login to get access

Abstract

Objective

Several studies have suggested that hydration and sodium load might reduce nephrotoxicity related to amphotericin B-deoxycholate (AmB-d). However, a schedule of these nephroprotective measures has not been standardized until now. A protocol of hydration and electrolyte supplementation was used prospectively in patients with hematological malignancies receiving empirical AmB-d treatment to evaluate its effect on AmB-d-related renal toxicity.

Patients and methods

A total of 77 consecutive patients received AmB-d (1 mg/kg per day) in association with an initial intravenous hydration of at least 1 l/m2 body surface, containing at least 1 l of 0.9% saline daily. Hydration was increased when serum creatinine levels showed a 20% increase from baseline. Serum electrolytes were replaced when indicated.

Results

The median duration of AmB-d therapy was 14 days. The mean intravenous hydration and the mean diuresis were 1530 and 1970 ml/m2 of body surface per day, respectively. Overall, 55 patients (71.4%) received a mean of 18.5 days of therapy without dose-limiting adverse events. Despite significant increases in mean creatinine serum levels and decreases in mean creatinine clearance observed early in the whole population, in only six patients (7.8%) was therapy discontinued due to renal failure, which always recovered after treatment discontinuation. In eight patients (10.4%) therapy was stopped due to infusion-related side effects. Seven patients died while under antifungal therapy without relevant signs of AmB-d-associated toxicity.

Conclusions

Our prospective experience confirms that adequate hydration (about 1500 ml/m2 of body surface) and careful electrolyte supplementation are simple measures able to contain nephrotoxicity and to permit adequate antifungal therapy at least in the empirical setting.
Literature
1.
go back to reference Bates DW, Su L, Yu T, Chertow GM, Seger DL, Gomes DRJ, Dasbach EJ, Platt R (2002) Mortality and cost of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686–693 Bates DW, Su L, Yu T, Chertow GM, Seger DL, Gomes DRJ, Dasbach EJ, Platt R (2002) Mortality and cost of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686–693
2.
go back to reference Branch RA, Jackson EK, Jacqz E, Stein R, Ray WA, Ohnhaus EE, Meusers P, Heidemann H (1987) Amphotericin B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr 65:500–506 Branch RA, Jackson EK, Jacqz E, Stein R, Ray WA, Ohnhaus EE, Meusers P, Heidemann H (1987) Amphotericin B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr 65:500–506
3.
go back to reference Branch RA (1988) Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 148:2389–2394 Branch RA (1988) Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 148:2389–2394
4.
go back to reference Butler WT, Bennett JE, Ailing DW, Wertlake PT, Utz JR, Hill GJ (1964) Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 61:175–187 Butler WT, Bennett JE, Ailing DW, Wertlake PT, Utz JR, Hill GJ (1964) Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 61:175–187
5.
go back to reference Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, Arndt CA, Schuster M, Seibel N, Yeldandi V, Tong KB (2000) Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 18:2476–2483 Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, Arndt CA, Schuster M, Seibel N, Yeldandi V, Tong KB (2000) Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 18:2476–2483
6.
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMed Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMed
7.
go back to reference Feely J, Heidemann H, Gerkens J, Roberts LJ, Branch RA (1981) Sodium depletion enhances nephrotoxicity of amphotericin B. Lancet 1:1422–1423 Feely J, Heidemann H, Gerkens J, Roberts LJ, Branch RA (1981) Sodium depletion enhances nephrotoxicity of amphotericin B. Lancet 1:1422–1423
8.
go back to reference Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL (1989) Risk factors for amphotericin B associated nephrotoxicity. Am J Med 87:547–552 Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL (1989) Risk factors for amphotericin B associated nephrotoxicity. Am J Med 87:547–552
9.
go back to reference Furrer K, Schaffner A, Vavricka SR, Halter J, Imbof A, Schanz U (2002) Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogeneic stem cell transplantation. Swiss Med Wkly 132:316–320 Furrer K, Schaffner A, Vavricka SR, Halter J, Imbof A, Schanz U (2002) Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogeneic stem cell transplantation. Swiss Med Wkly 132:316–320
10.
go back to reference Gallis HA, Drew RH, Pickard WW (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12:308–329 Gallis HA, Drew RH, Pickard WW (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12:308–329
11.
go back to reference Girmenia C, Gentile G, Micozzi A, Martino P (2001) Nephrotoxicity of amphotericin B desoxycholate. Clin Infect Dis 33:915–916 Girmenia C, Gentile G, Micozzi A, Martino P (2001) Nephrotoxicity of amphotericin B desoxycholate. Clin Infect Dis 33:915–916
12.
go back to reference Girmenia C, Cimino G, Micozzi A, Gentile G, Martino P (2002) Risk factors for nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 113:351 Girmenia C, Cimino G, Micozzi A, Gentile G, Martino P (2002) Risk factors for nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 113:351
13.
go back to reference Harbarth S, Burke JP, Lloyd JF, Evans S, Pestotnik SL, Samore MH (2002) Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35:e120–e127 Harbarth S, Burke JP, Lloyd JF, Evans S, Pestotnik SL, Samore MH (2002) Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35:e120–e127
14.
go back to reference Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH (2001) The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 111:528–534 Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH (2001) The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 111:528–534
15.
go back to reference Heidemann HAT, Gerkens JF, Spickard WA, Jackson EK, Branch RA (1983) Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 75:476–481 Heidemann HAT, Gerkens JF, Spickard WA, Jackson EK, Branch RA (1983) Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 75:476–481
16.
go back to reference Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRefPubMed Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRefPubMed
17.
go back to reference Imhof A, Waler RB, Schaffner A (2003) Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 36:943–951 Imhof A, Waler RB, Schaffner A (2003) Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 36:943–951
18.
go back to reference Johnson JR (2004) Reduction of nephrotoxicity associated with amphotericin B deoxycholate. Clin Infect Dis 38:303 Johnson JR (2004) Reduction of nephrotoxicity associated with amphotericin B deoxycholate. Clin Infect Dis 38:303
19.
go back to reference Luber AD, Maa L, Lam M, Guglielmo BJ (1999) Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 43:267–271 Luber AD, Maa L, Lam M, Guglielmo BJ (1999) Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 43:267–271
20.
go back to reference Mayer J, Doubek M, Vorlicek J (1999) Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer 7:51–55 Mayer J, Doubek M, Vorlicek J (1999) Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer 7:51–55
21.
go back to reference Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M (2002) Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 186:379–388 Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M (2002) Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 186:379–388
22.
go back to reference Ohnishi A, Ohnishi T, Stevenhead W, Robinson RD, Glick A, O’Day DM, Sabra R, Jackson EK, Branch RA (1989) Sodium status influences chronic amphotericin B nephrotoxicity in rats. Antimicrob Agents Chemother 33:1222–1227 Ohnishi A, Ohnishi T, Stevenhead W, Robinson RD, Glick A, O’Day DM, Sabra R, Jackson EK, Branch RA (1989) Sodium status influences chronic amphotericin B nephrotoxicity in rats. Antimicrob Agents Chemother 33:1222–1227
23.
go back to reference Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new “gold standard”. Clin Infect Dis 37:415–425 Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new “gold standard”. Clin Infect Dis 37:415–425
24.
go back to reference Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161–189CrossRefPubMed Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161–189CrossRefPubMed
25.
go back to reference Pathak A, Pien FD, Carvalho L (1998) Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis 26:334–338 Pathak A, Pien FD, Carvalho L (1998) Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis 26:334–338
26.
go back to reference Sabra R, Branch RA (1990) Amphotericin B nephrotoxicity. Drug Saf 5:94–108 Sabra R, Branch RA (1990) Amphotericin B nephrotoxicity. Drug Saf 5:94–108
27.
go back to reference Spellberg B, Witt MD, Beck CK (2004) Amphotericin B: is a lipid-formulation gold standard feasible? Clin Infect Dis 38:304–305 Spellberg B, Witt MD, Beck CK (2004) Amphotericin B: is a lipid-formulation gold standard feasible? Clin Infect Dis 38:304–305
28.
go back to reference Stein RS, Alexander JA (1989) Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am Med Sci 298:299–304 Stein RS, Alexander JA (1989) Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am Med Sci 298:299–304
29.
go back to reference Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey G (2000) Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30:696–709CrossRefPubMed Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey G (2000) Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30:696–709CrossRefPubMed
30.
go back to reference Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New Engl J Med 340:764–771 Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New Engl J Med 340:764–771
31.
go back to reference Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29:1402–1407 Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29:1402–1407
Metadata
Title
Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies
Authors
Corrado Girmenia
Giuseppe Cimino
Francesca Di Cristofano
Alessandra Micozzi
Giuseppe Gentile
Pietro Martino
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 12/2005
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0783-x

Other articles of this Issue 12/2005

Supportive Care in Cancer 12/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine